🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Universitaire Dijon
NCT06948656 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Fasting blood glucose is maintained by hepatic production of glucose from glycogenolysis or gluconeogenesis. In cirrhosis, glycogen storage capacity is reduced, with a consequent increase in gluconeogenesis to maintain blood glucose levels. Hypoglycaemia is particularly common during periods of prolonged nocturnal fasting. Cirrhosis can therefore be considered an 'accelerated fasting' disease. In a recent study, Honda et al. described 22% nocturnal hypoglycaemia in 105 patients analysed continuously. A previous study showed that the percentage of hypoglycaemia over the total duration of continuous blood glucose recording averaged 4%. This gluconeogenesis could lead to a significant increase in muscle and fat catabolism, which would aggravate sarcopenia and lead to undernutrition. Undernutrition and sarcopenia are serious and severe in cirrhotic patients. Sarcopenia, present in around 45

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * Age ≥18 years * Person with oral consent * Patient with cirrhosis according to the 2021 EASL criteria (1) * Patient receiving regular six-monthly and systematic monitoring of cirrhosis, according to the European recommendations of the EASL (2), or French recommendations of the TNCD (3) and HAS (4), including a clinical examination, a biological work-up (to calculate the CHILD-PUGH score and monitor alpha-feto-protein), AND requiring imaging to screen for HCC of hepatocellular carcinoma using cross-sectional imaging (by MRI and/or hepatic CT scan). Exclusion Criteria: * Patients with active cancer or treated within the last 6 months * Patient with an acute episode of cirrhosis decompensation (ongoing antibiotic treatment for an active infection, gastrointestinal bleeding, hepatic encephalopathy, acute alcoholic hepatitis) less than one month old. * Treatment with systemic corticosteroids, in progress or within the last 3 months * Patient with organ transplant * Person not affiliated to or not benefiting from a social security scheme * Person under legal protection (curatorship, guardianship) * Person subject to a legal protection measure * Pregnant or breast-feeding women * An adult who is incapable or unable to give consent * Minors * Patients already included in an interventional study who may interfere with the evaluation of this study.
💊

What it tests

  • fitting a blood glucose sensor
  • food collection
  • tests and questionnaires
📍

Where

1 site
CHU Dijon Bourgogne
Dijon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy